CURRICULUM VITAE

Firdos Ahmad, PhD

Associate Professor
College of Medicine
Sharjah Institute for Medical Research
University of Sharjah, Sharjah, 27272 UAE
E-mails: fahmad@sharjah.ac.ae

Professional Experience

Associate Professor Department of Basic Medical Sciences, University of Sharjah, Sharjah, UAE	2021-present
Assistant Professor Department of Basic Medical Sciences, University of Sharjah, Sharjah, UAE	2017- 2021
Assistant Professor Division of Cardiovascular Medicine, Vanderbilt University, Nashville, TN, USA	2014- 2016
Post-Doctoral Fellows Center for Translational Medicine, Temple University, Philadelphia, PA, USA	2012- 2014
Post-Doctoral Fellow Department of Medicine, Thomas Jefferson University, Philadelphia, PA, USA	2009- 2012
Senior Research Fellow All India Institute of Medical Sciences, New Delhi, India	2008- 2009
Visiting Scientist (Prof. Gunther Landbeck Fellow) University Medical Center Eppendorf, Hamburg, Germany	2007- 2008
Junior Research Fellow All India Institute of Medical Sciences, New Delhi, India	2004- 2007

Education

Ph.D. (Clinical Genetics, Hematology)	2009	All India Institute of Medical Sciences (AIIMS), New Delhi, India/ University Medical Center Hamburg Germany
M.Sc. (Toxicology)	2004	Hamdard University, New Delhi, India
B.Sc. (Biology, Chemistry)	2000	University of Lucknow, Lucknow, India

Scientific Memberships

1. American Heart Association (AHA)
2. European Society of Cardiology (ESC)
3. American Society of Hematology (ASH)

Honors/Awards

- **Paul Dudley White International Scholar award** from American Heart Association for Highest Ranked Abstract from UAE in BCVS Scientific Session, August 2021
- **Pier M. Mannucci Young Investigator award** for research article "Relative contribution of STIM1 and CalDAG-GEFI to calcium-dependent platelet activation and thrombosis. *J Thromb Haemost*. 2011;9(10):2077-86" as one of the best published articles in 2011
- **U.S. New Investigator Travel Award** from Boston International Society of Thrombosis and Hemostasis (ISTH) Committee for high rated research abstract for XXIII conference of ISTH held (July 23-28th 2011) in Kyoto Japan (conference not attended)
- **American Society of Hematology (ASH) Travel Award** by ASH committee 2010 for high rated research abstract at annual meeting held (Dec 4-7, 2010) in Orlando, Florida, USA
- **Developing World Scientist award** by 22nd International Society of Thrombosis and Hemostasis (ISTH) committee, meeting held (July 11th-16th 2009) in Boston, USA
- **Reach the world Young Scientist award** by 54th Annual committee Meeting of the Scientific and Standardization Committee (SSC) of International Society of Thrombosis and Hemostasis (ISTH) held (July 2nd-5th 2008) in Vienna, Austria
- **Prof. Guenther Landbeck Fellowship award** by University Medical Center Eppendorf, Hamburg, Germany (Sept 2007-March 2008)

Ad-hoc Reviewer in international Journals:

European Heart Journal, Circulation, Circulation Research, Frontiers in Pharmacology, J. Am Heart Association, Hematology, Molecular and Cellular Biochemistry, Bioengineered,

Publications:

1. Shahzadi SK, Marzook H, Qaisar R, **Ahmad F.** Nicotinamide riboside kinase-2 inhibits JNK pathway and limits dilated cardiomyopathy in mice with chronic pressure overload *Clin Sci (Lond).* 2022 Jan 28;136(2):181-196.
2. Yusuf AM, Qaisar R, Al-Tamimi AO, Jayakumar MN, Woodgett JR, Koch WJ, **Ahmad F.** Cardiomyocyte-GSK-3β deficiency induces cardiac progenitor cell proliferation in the ischemic heart through paracrine mechanisms. *J Cell Physiol.* 2021 Nov 23. doi: 10.1002/jcp.30644.
3. **Ahmad F,** Kannan M, Ansari AW. Role of SARS-CoV-2 -induced cytokines and growth factors in coagulopathy and thromboembolism. *Cytokine Growth Factor Rev* 2021 Oct 24;S1359-6101(21)00079-4.
4. **Ahmad F**, Tomar D, Aryal A C S, Elmoselhi AB, Thomas M, Elrod JW, Tilley DG, Force T. Nicotinamide riboside kinase-2 alleviates ischemia-induced heart failure through P38 signaling. *Biochim Biophys Acta Mol Basis Dis.* 2020; 1866(3):165609
5. **Ahmad F**, Woodgett JR. Emerging roles of GSK-3α in pathophysiology: Emphasis on cardio-metabolic disorders. *Biochim Biophys Acta Mol Cell Res*. 2020;1867(2):118616.

6. Kannan M, **Ahmad F,** Saxena R. Platelet activation markers in evaluation of thrombotic risk factors in various clinical settings. *Blood Reviews 2019 Sept;37:100583*.

7. **Ahmad F,** Singh AP, Tomar D, Rahmani M, Zhang Q, Woodgett JR, Tilley DG, Lal H, Force T. Cardiomyocyte-GSK-3α promotes mPTP opening and heart failure in mice with chronic pressure overload. *J Mol Cell Cardiol*. 2019 Mar 27;130:65-75.

8. **Ahmad F,** Kannan M, Obser T, Budde U, Schneppenheim S, Saxena R, Schneppenheim R. Characterization of VWF gene conversions causing von Willebrand disease. *Br J Haematol*. 2019 Mar;184(5):817-825.

9. **Ahmad F.** Vaccination: a novel potential therapeutic approach to limit thrombosis. *J Am Heart Assoc.* 2018 Jun 23;7(13). pii: e009861

10. Gupte M, Tumuluru S, Sui J, Singh AP, Umbarkar P, Parikh S, **Ahmad F**, Zhang Q, Force T, Hind Lal. Cardiomyocyte-Specific Deletion of GSK-3β Leads to Cardiac Dysfunction in a Diet Induced Obesity Model. *Int J Cardiol.* 2018: 259;145–152

11. Gupte M, Lal H **Ahmad F**, Sawyer DB, Hill MF. Chronic Neuregulin-1B Treatment Mitigates the Progression of Post-Myocardial Infarction Heart Failure in the Setting of Type 1 Diabetes Mellitus by Suppressing Myocardial Apoptosis, Fibrosis and Key Oxidant-Producing Enzymes. *J Card Fail*. 2017: S1071-9164(17)31159-4.

12. Zhou J*, **Ahmad F***, Lal H, Force T. Response by Zhou et al to Letter Regarding Article, "Loss of Adult Cardiac Myocyte GSK-3 Leads to Mitotic Catastrophe Resulting in Fatal Dilated Cardiomyopathy". Invited commentary *Circ Res*. 2016;119:e29-e30 *Equal first author

13. Zhou J*, **Ahmad F***, Parikh S, Hoffman NE, Rajan S, Verma VK, Song J, Yuan A, Shanmughapriya S, Guo Y, Gao E, Koch W, Woodgett JR, Madesh M, Kishore R, Lal H, Force T. Loss of Adult Cardiac Myocyte GSK-3 Leads to Mitotic Catastrophe Resulting in Fatal Dilated Cardiomyopathy. *Circ Res* 2016: 118;1208-1222. *Equal first author

14. Lal H, **Ahmad F,** Woodgett JR, Force T. The GSK-3 family as a therapeutic target for myocardial diseases. *Circ Res.* 2015 Jan 2;116(1):138-149.

15. **Ahmad F**, Lal H, Zhou J, Vagnozzi RJ, Yu JE, Shang X, Woodgett JR, Gao E, Force T. Cardiomyocyte specific deletion of *Gsk3α* mitigates post-myocardial infarction remodeling, contractile dysfunction, and heart failure. *J Am Col Cardiol* 2014;64(7):696-706

16. Lal H*, **Ahmad F***, Zhou J, Yu JE, Vagnozzi RJ, Guo Y, Yu D, Tsai JE, Woodgett JR, Gao E, Force T. Cardiac fibroblast GSK-3β regulates ventricular remodeling and dysfunction in ischemic heart. *Circulation* 2014;130(5)419-30. *Equal first author (**Faculty of 1000 rating:****)

17. Lal H, **Ahmad F**, Parikh S, Force T. TNNI3K, a novel cardiac-specific kinase, emerging as a molecular target for the treatment of cardiac disease. *Circulation J* 2014 Jun 25;78(7):1514-9. *Invited Review*

18. **Ahmad F**, Oyen F, Jan R, Budde U, Schneppenheim R, Saxena R. Germline *de novo* mutations and linkage markers versus DNA sequencing for carrier detection in von Willebrand disease. *Haemophilia* 2014 Jul;20(4):e311-7

19. Zhou J, Freeman TA, **Ahmad F**, Shang X, Mangano E, Gao E, Farber J, Wang Y,Ma X, Woodgett J, Vagnozzi RJ, Lal H, Force T. GSK-3α is a central regulator of age-related pathologies in mice**.** *J Clin. Invest* 2013;123(4);1821-1832.

20. **Ahmad F**, Budde U, Jan R, Oyen F, Kannan M, Saxena R, Schneppenheim R. Phenotypic and molecular characterisation of type 3 von Willebrand disease in a cohort of Indian patients. *Thromb Haemost* 2013;109(4);652-660.

21. **Ahmad F**, Jan R, Kannan M, Obser T, Hassan MI, Oyen F, Budde U, Saxena R, Schneppenheim R. Characterisation of mutations and molecular studies of type 2 von Willebrand disease. *Thromb Haemost* 2013;109(1):39-46. (**Cover Page**)

22. Edelstein L, Luna E, Gibson I, Bray M, Jin Y, Kondkar I, Nagalla S, Smith T, Hadjout-Rabi N, Covarrubias D, Jones SN, **Ahmad F**, Stolla M, Kong X, Dong J, Bergmeier W, Shaw C, Leal S and Bray PF. Human Genome-Wide Association and Mouse Knockout Approaches Identify Platelet Supervillin as an Inhibitor of Thrombus Formation under Shear Stress. *Circulation* 2012;125(22):2762-71.

23. Lal H, Zhou J, **Ahmad F**, Zaka R, Vagnozzi RJ, DeCaul M, Woodgett J, Gao E, Force T. GSK-3α Limits Ischemic Injury, Cardiac Rupture, Post- Myocardial Infarction Remodeling and Death. *Circulation* 2012;125(1):65-75.

24. Pandey S, Ranjan R, **Ahmad F**, Shah V, Pandey SW, Mishra RM, Seth T, Saxena R. Relation Between the Uridine Diphosphate Glucuronosyltransferase 1A1 Polymorphism and the Bilirubin Levels in Sickle Cell Disease. *Journal of Clinical and Diagnostic Research* 2012;6(5): 821-824

25. **Ahmad F**, Ouellette TD, Greene T, Poncz M, Feske S, Bergmeier W. Relative contribution of STIM1 and CalDAG-GEFI to calcium-dependent platelet activation and thrombosis**.** *J Thromb Haemost.* 2011;9(10):2077-86 (**Pier M. Mannucci Award winner**).

26. **Ahmad F,** Kannan M, Kishor K and Saxena R. Coinheritance of severe von Willebrand disease with Glanzmann Thrombasthenia. *Clin Appl Thromb Hemost* 2010;16(5):529-32.

27. **Ahmad F,** Kannan M, Yadav V, Biswas A and Saxena R. Impact of thrombogenic mutations on clinical phenotype of von Willebrand Disease. *Clin Appl Thromb Hemost* 2010;16(3):281-7.

28. **Ahmad F,** Kannan M, Biswas A and Saxena R. Impact of Ala789Ala genotype on quantitative type von Willebrand Disease. *Ann Hematol* 2009;88(5):479-83.

29. **Ahmad F**, Kannan M, Ranjan R, Bajaj J, Choudhary VP, Saxena R. Inherited Platelet function disorders versus others inherited bleeding disorders: An Indian overview. *Thromb Res* 2008;121(6):835-41.

30. **Ahmad F,** Kannan M, Biswas A, Choudhary VP and Saxena R. Gene tracking in a family of novel identical Twins affected by severe type 3 von Willebrand Disease. *Thromb Res* 2007;120 (3):459–462.

31. **Kannan M, Yadav BK, Ahmad F and Saxena R.** Role of RFLP using TspRI for carrier detection in Glanzmann's Thrombasthenia: A report on two families. *Int J Lab Hematol* 2010;32(1 Pt 1):e158-62.

32. **Kannan M, Ahmad F, Yadav BK, Kumar R,** Choudhry **VP, Saxena R**. Molecular defects in ITGA2B and ITGB3 genes in patients with Glanzmann's thrombasthenia. *J Thromb Haemost* 2009;7(11):1878-85 (**Cover page).**

33. **Kannan M, Chatterjee T, Ahmad F, Rajive Kumar, Choudhary VP and Saxena R.** Acquired Glanzmann's thrombasthenia associated with Hairy cell leukemia. *Eur J Clin Invest* 2009;39(12):1110-1.

34. **Kannan M, Yadav BK, Ahmad F, Biswas A and Saxena R.** Modulation of clinical phenotype in Glanzmann's Thrombasthenia. *Clin Chim Acta* 2009;403(1-2):156-8.

35. **Kannan M, Ahmad F, Yadav BK,**Mona A, Jain P,**Kumar R and Saxena R.** Glanzmann's Thrombasthenia in North Indians: Sub classification and carrier detection by flow cytometry. *Platelets* 2009;20(1):12-5.

36. **Kannan M**, **Ahmad F**, Yadav BK, Kumar P, Jain P, Kumar R and Saxena R. Carrier detection in Glanzmann's Thrombasthenia: Comparison of flow cytometry and western blot with respect to DNA mutation. *Am J Clin Pathol* 2008;130(1):93-98.

37. Panigrahi I, **Ahmad F**, Kapoor R, Sharma PK, Makharia G, Saxena R. Evidence for non-HFE linked hemochromatosis in Asian Indians. *Indian J Med Sci* 2006;60(12):491-495.

38. Kannan M, **Ahmad F**, Ahmad S, Kale S, Debra A. Hoppensteadt, Fareed J and Saxena R. HIT Antibodies in Heparin Induced Thrombocytopenia: Its Relationship with FcγRIIa Polymorphism. *Am J Immunol* 2005;1(1):55-59

39. Kannan M, Ahmad S, **Ahmad F**, Kale S, Debra A. Hoppensteadt, Fareed J and Saxena R. Functional characterization of antibodies against heparin–platelet factor 4 complex in heparin-induced thrombocytopenia patients in Asian- Indians: relevance to inflammatory markers. *Blood Coagul Fibrinolysis* 2005;16(7):487-90.

Conference abstracts published in Journals:

1. Shahzadi SK, Qaisar R, **Ahmad F.** Nicotinamide Riboside Kinase-2 Deficiency Promotes Pressure Overload- Induced Dilated Cardiomyopathy and Heart Failure. *Circ Res.* 2021;129: AP326. doi: 10.1161/res.129.suppl_1. P326.

2. Al-Tamimi AO, Yusuf AM, Jayakumar MN, Ansari AW, Elhassan M, AbdulKarim F, Kannan M, Rabih Halwani R, **Ahmad F.** Abstract P357: Induction Of Soluble P-selectin And CD40 Ligand And, FXIII Deficiency Promote Aberrant Coagulation And Thromboembolism In Severe COVID-19. *Circ Res.* 2021;129: AP357. DOI: 10.1161/res.129.suppl_1. P357.

3. Yusuf AM, Qaisar R, Woodgett JR, **Ahmad F.** GSK-3β Deficiency In Cardiomyocyte Induces Cardiac Progenitor Cell Proliferation In The Ischemic Heart. *Circ Res.* 2021;129: AP409. /doi.org/10.1161/res.129.suppl_1. P409.

4. Gupta M, Tumuluru S, Singh AP, Umbarkar P, Zhang Q, **Ahmad F**, Parikh P, Force T, Lal H, Cardiomyocyte-specific Conditional Deletion of GSK-3β Leads to Cardiac Dysfunction in a High Fat Diet Induced Obesity Model. *Circ Res 2017; 121 (Suppl 1), A41.*

5. Gupta M, Lal H **Ahmad F**, Sawyer DB, Hill MF. Chronic Neuregulin-1β Treatment Mitigates the Progression of Post-myocardial Infarction Heart Failure in the Setting of Type 1 Diabetes Mellitus. *Circ Res 2017; 121 (Suppl 1), A33.*

6. **Ahmad F**, Lal H, Verma VK, Woodgett JR, Force T. Cardiomyocyte GSK-3α Signaling Exacerbate Pressure Overload-induced Dilated Cardiomyopathy and Heart Failure. *Circ Res 2016:;119:A69*

7. Lal H, **Ahmad F**, Verma VK, Tumuluru S, Parikh S, Zhang Q, Force T. Cardiomyocyte-specific Conditional Deletion of GSK-3β Leads to Global Metabolic Defects and Cardiac Dysfunction in a HFD Induced Obesity Model. *Circ Res 2016;119: A75*

8. Verma VK, **Ahmad F**, Zhang Q, Force T, Lal H. Cardiac fibroblast-specific deletion of GSK-3α alleviate from cardiac dysfunction and fibrotic remodeling in ischemic heart. *Circ Res 2016:2016;119:A280*

9. Zhou J, **Ahmad F**, Lal H, Parikh S, Hoffman NE, Rajan S, Shanmughapriya S, Zhang X, Guo Y, Yuan A, Song J, Chan X, Madesh M, Woodgett JR, Kishore R, Force T. Cardiac-specific deletion of GSK-3α and β leads to fatal dilated cardiomyopathy with mitotic catastrophe. *Circulation*. 2014;130:A13350

10. **Ahmad F**, Lal H, Vagnozzi RJ, Zhou J, Woodgett J, Gao E, Force T. Cardiac specific deletion of Glycogen Synthase Kinase-3α attenuates post myocardial infarction-induced ventricular remodeling and preserves heart function. *Circ Res* 2012;111(e1-e9):22990

11. Lal H, **Ahmad F**, Vagnozzi RJ, Zhou J, Woodgett J, Gao E, Force T. Cardiac specific deletion of Glycogen Synthase Kinase-3α attenuates post myocardial infarction-induced ventricular remodeling and preserves heart function. *Circ Res*2012;111(e1-e9):22983

12. **Ahmad F**, Stefanini L, Ouellette TD, Greene TK, Feske S, and Bergmeier W. STIM1 Deficiency Results In Impaired Platelet Procoagulant Activity and Protection From Arterial Thrombosis. *J Thromb Haemost* 2011;9(S2):736

13. **Ahmad F,** Schneppenheim R, Oyen F, Obser T, Kannan M and Saxena R. Mutation spectrum and characterization of two novel large deletions causing severe type 3 von Willebrand disease. *J Thromb Haemost* 2011;9(S2):19

14. **Ahmad F**, Stefanini L, Ouellette TD, Greene TK,Feske S, and Bergmeier W. STIM1 Deficiency Results In Impaired Platelet Procoagulant Activity and Protection From Arterial Thrombosis.*Blood*2010;116: 485

15. Stolla M, Stefanini L, Ouellette TD, **Ahmad F**, Reilly MP, McKenzie S, and Bergmeier W. Critical Role of CalDAG-GEFI in FCγRIIa-dependent platelet Activation and thrombosis.*Blood* 2010;116: 3196

16. **Ahmad F**, Schneppenheim R, Oyen F, Obser T, Budde U, Hasan I, Kannan M and Saxena R.Mutation spectrum and molecular studies of type 2 von Willebrand disease:*J ThrombHaemost* 2009;7:638

17. Kannan M, Yadav BK, **Ahmad F**, Fareed J and Saxena R. Thrombogenic mutations in glanzmann's thrombasthenia patients. *J Thromb Haemost* 2009;7:037

18. **Ahmad F**, Schneppenheim R, Oyen F, Obser T, Budde U, Kannan M and Saxena R. Mutation spectrum of severe von Willebrand disease type 3 in India. *Haematologica* 2009;94(2):43

19. **Ahmad F**, Schneppenheim R, Oyen F, Obser T, Kannan Mand Saxena R. Characterization of two novel large deletions causing von Willebrand disease type 3. *Hämostaseologie* 2009;29:3.2-1

20. Kannan M, **Ahmad F**, Saxena R, Fareed J. Higher Prevalence of Heparin-Induced Thrombocytopenia Antibodies in Asian Indian Population: Is This Due to Contaminated Heparin? *Blood* (2009) 114 (22): 4182

21. **Ahmad F,** Kannan M, Yadav BK and Saxena R. Variable number of tandem repeats and other polymorphic linkage are not accurate markers for carrier detection of von Willebrand disease**.** *Am J Clin Pathol* 2008;130:652

22. Kannan M, **Ahmad F**, Yadav BK, Kumar R, Fareed J and Renu Saxena. Patients with No Mutations in Both the ITGA2B and ITGB3 Genes as Identified by Conformation Sensitive Gel Electrophoresis (CSGE). *Blood* 2008;112: 1236

23. Kannan M, **Ahmad F**, Yadav BK, Kumar R, Fareed J and Saxena R. Mutation Screening of GPIIb and GPIIIa Exons by Conformation Sensitive Gel Electrophoresis. *Blood*2007; 110: 3218

24. Kannan M, **Ahmad F**, Yadav BK, Kumar R and Saxena R.Evaluation of molecular genetics of Indian Glanzmann's Thrombasthenia and determination of its role for carrier detection. Selected for Dr. JC Patel best paper award,48th Annual conference of Indian Society of Hematology and Transfusion Medicine at Lucknow, 15th to 17th Nov 2007

25. Kannan M**, Ahmad F**, Kumar R, Choudhry VP and Saxena R. Use of CSGE, TspRI- RFLP and Western blot in Carrier Detection in an Indian family with Type I Glanzmann Thrombasthenia. *Blood* 2006; 108: 3975

26. Kannan M, **Ahmad F,** Ahmad S, Kale S, Fareed J and Saxena R. FcγRIIa Platelet Polymorphism in Asian Indians: Its Association with Development of Heparin Induced Thrombocytopenia**.** *J Thromb Haemost* 2005; 3(1):913

27. M. Kannan, S. Ahmad, **Ahmad F,** S. Kale, J. Fareed, R. Saxena, Testing of heparin-PF4 antibodies in Indian HIT patients: Relevance to FcγRIIa polymorphism and inflammation. *Pathophysiol Haemos Thromb* 2006;35:199-248

28. Kannan M**, Ahmad F**, Kale S, Saxena R. Fc gamma RIIa polymorphism and its association with Heparin Induced Thrombocytopenia in Asian Indians**.** *ISARCON* 2005, New Delhi, India

Talk in meetings/ conferences:

- Delivered a invited talk on "NRK-2, a Novel Regulator of Ischemic Cardiac Disease" in 7th Emirati-German conference (November 2019) at University of Sharjah
- Delivered a seminar on "Novel roles of glycogen synthase kinase-3α in hypertensive cardiac disease" (March 2019) at department of Basic Medical Sciences, University of Sharjah
- Delivered a talk on "Potential therapeutic targets in cardiovascular diseases" (January 2018) at Sharjah Institute for Medical Research (SIMR), University of Sharjah.
- Delivered a talk at "Late Breaking Oral session" of **American Heart Association Scientific Session** 2012 meeting at Los Angeles, CA, USA.
- Presented our work on "STIM1 deficiency results in impaired platelet procoagulant activity and protection from arterial thrombosis" at 52nd annual meeting of **American Society of Hematology (ASH)** held at Orlando Florida (Dec 4-7, 2010) USA.
- Delivered a talk at **40th Annual Workshop on Hemostasis, Thrombosis and Atherosclerosis** (Friday, Nov 19 2010) held at Temple University Philadelphia, USA.
- Presented our research work on **'Stromal Interaction molecule 1 in Platelet regulate pro-coagulation and thrombosis'** in Platelet meeting, University of Pennsylvania, Philadelphia, USA

Teaching activities:

1. **MBBS and BDS students**
    - Clinical Genetics
2. **Masters and PhD students**
    - Biomedical Genomics,
    - Human Molecular Genetics,
    - Animal animal models in biomedical research,
    - Advanced Techniques in Molecular Biology,
    - Cell Biology,
    - Vascular biology
3. Teach integrated and traditional curriculum.
4. **Unit coordinator:** Neurosciences Unit for MBBS curriculum (September 2018- August 2021)
5. Unit co-coordinator for Neuropsychiatry and Special Senses units for MBBS curriculum
6. **Problem-based learning (PBL) facilitator:** MBBS curriculum (September 2017- present)
7. Conducting PBL, TBL, EBL, Practical and professional development sessions.
8. Assess student learning and assignment of grades based on acceptable evaluation tools.
9. Delivery of course content in medical, dental and physiotherapy programs.
10. Contribution to the design, construction and implementation of learning modules in integrated medical curriculum.
11. **Aim:** To achieve an enhanced and blended learning approach in teaching Genetics, Cell and Molecular Biology through interactive and laboratory sessions.
12. **Mode of teaching:** Interactive smart board, LCD, hp projector, Blackboard, MS Teams.

Member of University & College Committees:

a. Animal Care and Use Committee, University of Sharjah (Nov 2017- Present)
b. College of Medicine Research Committee (Oct 2017- Present)
c. College of Medicine Curriculum committee (Sep 2019- Aug 2021)
d. Program Evaluation & Educational Quality Assurance & Accreditation (Sep 2022- Present)
e. College of Medicine Annual Research Day committee (Jan-Feb, 2019)

Basic Medical Sceinces Seminar coordinator at College of Medicine, University of Sharjah (2018-2019)

Master thesis supervision (Molecular Medicne):

Thesis title: Glycogen Synthase Kinase-3α Regulates Cardiomyopathy In a Model of Ischemia/Reperfusion
Session: 2018-2020

Thesis title: Paracrine roles of Glycogen Synthase Kinase-3β in Cardiac stem cell proliferation
Session: 2020-2022 (in progress)

Thesis title: Pathomechanisms of thromboembolic complications in severe COVID-19
Session: 2020-2022 (in progress)